Qiagen stock expands its sepsis testing portfolio

Published on 09/30/2026 at 14:55 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Qiagen stock gets a new U.S. sepsis testing panel after FDA clearance on September 28, 2026. Q2 adjusted EPS beat consensus while 2026 guidance stayed at USD 2.43.

Pipette tropft klare Flüssigkeit in sterile 96-Well-Platte, klinisches Laborlicht — Qiagen N.V. (NL0012169213) Pipette tropft klare Flüssigkeit in sterile 96-Well-Platte im klinischen Labor, Illustration mit AI erstellt.

Qiagen N.V. (ISIN NL0012169213) completed a U.S. bloodstream infection testing portfolio covering 33 pathogen targets and 28 antibiotic resistance markers. The FDA clearance announced on September 28, 2026 gives laboratories access to the full QIAstat-Dx menu, adding a concrete product catalyst to a company still managing cautious research spending.

FDA clearance broadens the menu

According to Qiagen on September 28, 2026, the new QIAstat-Dx BCID GN Plus AMR Panel identifies 13 gram-negative bacterial targets and 18 resistance markers. Together with the existing panel for gram-positive bacteria and fungi, the portfolio reaches 33 targets and 28 markers.

The release also said QIAstat-Dx had more than 5,200 cumulative placements at the end of 2025 and was available in more than 100 countries. That installed base matters because a broader test menu can support recurring consumables revenue after instruments are placed.

Q2 beat meets cautious outlook

Zacks reported on September 24, 2026 that QIAGEN delivered second-quarter 2026 adjusted EPS of USD 0.62, 3.3 percent above consensus. Net sales reached USD 535 million, 1.4 percent above the consensus mark, while GAAP EPS was USD 0.50 versus USD 0.44 in the year-ago quarter.

QIAGEN reaffirmed 2026 guidance for sales growth of 1-2 percent at constant exchange rates and adjusted EPS of at least USD 2.43. Management expects second-half sales growth of 3-4 percent at constant exchange rates, compared with a 1 percent decline in the first half, creating a clear execution test for the new diagnostic menu.

Execution remains the key test

The product expansion does not remove demand risks. Zacks said cautious customer spending, weaker research funding and competition could delay platform adoption, while QIAGEN's second-quarter PCR and nucleic acid amplification revenue fell 8 percent at constant exchange rates.

Qiagen trades below yearly high

QIAGEN was last at USD 44.40 on the NYSE on September 29, 2026 at 4:00 p.m. ET. Its market capitalization was USD 9.2 billion and its 52-week range was USD 32.53 to USD 57.82 as of that date, leaving execution of the 2026 outlook as the central valuation question.